Verdinexor (KPT-335)
-
Verdinexor (KPT-335)
structure -
-
CAS No:
1392136-43-4
-
Formula:
C18H12F6N6O
-
Chemical Name:
Verdinexor (KPT-335)
-
Synonyms:
Z)-3-(3-(3,5-bis(trifluoroMethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-;KPT-335;Verdinexor;Verdinexor(KPT-335);(2Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]- 2-propenoic acid-2-(2-pyridinyl)hydrazide;(2Z)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N -(pyridin-2-yl)prop-2-enehydrazide Verdinexor(KPT-335);(KPT335)(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-2-yl)acrylohydrazide
- Categories:
-
CAS No:
Description
Kpt 335 is under investigation in clinical trial NCT02431364 (Trial of Safety and Tolerability of Oral Verdinexor (Verdinexor) in Healthy Adults).
Verdinexor (KPT-335) Use and Manufacturing
Synthesis of (Z)-3-(3-(3, 5-bis(trifluoromethyl)phenyl)-lH-l, 2, 4- -yl)-N'-(pyridin-2-yl)acrylohydrazide hydrochloride (1-4).A 500-mL, 3 -necked, round-bottomed flask was charged with a suspension of (Z)-3- (3-(3, 5-bis(trifluoromethyl)phenyl)-lH-l , 2, 4-triazol-l-yl)acrylic acid (10 g, 1.0 eq.) in 1 : 1 CH2C12:AcOEt (200 mL). 2-Hydrazinopyridine (3.1 1 g) was added at -40°C. T3P (50percent in ethylacetate) (21.75 g) was added dropwise followed by DIPEA (7.36 g) and the reaction mixture was stirred for 30 min at -40 °C before being concentrated under reduced pressure (35 °C, 20 mm Hg) to afford a crude brown oil that was purified by column chromatography (the compound eluted with 1.3percent MeOH in CH
Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
Computed Properties
Molecular Weight:442.3
XLogP3:4.1
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:11
Rotatable Bond Count:5
Exact Mass:442.09767800
Monoisotopic Mass:442.09767800
Topological Polar Surface Area:84.7
Heavy Atom Count:31
Complexity:620
Defined Bond Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes
Latest News on Verdinexor (KPT-335)
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
Dabrafenib
1195765-45-7
-
BOC-VAL-VAL-OH
69209-73-0
-
BMS 303141
943962-47-8
-
(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula
60117-17-1
-
(2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula
57899-96-4
-
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula
26130-02-9
-
L-Tyrosyl-L-phenylalanine Structure
17355-11-2
-
C-REACTIVE PROTEIN FRAGMENT 77-82 Structure
130349-01-8
-
What is Sildenafil
139755-83-2
-
What is Dacomitinib
1110813-31-4